Alternative links to fulltext:
Abstract
The antitumor activity of stereoisomers of the title complex (I) in several tumor models (MDA-MB 231 breast cancer cell line; mouse P 388 leukemia, mouse L 1210 leukemia, rat L 5222 leukemia, and mouse wild-type Ehrlich ascites tumor resistant to cisplatin, etoposide, cyclophosphamide, and daunomycin, resp.) is described. For comparison, the analogous ...
Abstract
The antitumor activity of stereoisomers of the title complex (I) in several tumor models (MDA-MB 231 breast cancer cell line; mouse P 388 leukemia, mouse L 1210 leukemia, rat L 5222 leukemia, and mouse wild-type Ehrlich ascites tumor resistant to cisplatin, etoposide, cyclophosphamide, and daunomycin, resp.) is described. For comparison, the analogous [1,2-bis(4-hydroxyphenyl)ethylenediamine]dichloroplatinum (II)-complexes are used. The antitumor activity of the combination of I stereoisomers with cisplatin is reported. Structure-activity relations are described.
Altmetric